Selbst. Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie
 Universitätsmedizin Leipzig


Hier finden Sie unsere Publikationen zum Neuroblastom.

Fest S, Soldati R, Christiansen NM, Zenclussen ML, Kilz J, Berger E, Starke S, Lode HN, Engel C, Zenclussen AC, Christiansen H (2016): Targeting of Heme Oxygenase-1 as a novel immune regulator of neuroblastoma. Int J Cancer 138(8):2030-2042.

Berger E, Soldati R, Huebner N, Hohn O, Stermann A, Durmus T, Lobitz S, Zenclussen AC, Christiansen H, Lode HN and Fest S (2013): Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. Cancer Lett 331(2):167-173.
Weber A, Taube S, Starke S, Bergmann E, Christiansen NM and Christiansen H (2011): Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR). J Clin Invest 121(2):545-553.
Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Benard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, DeCarolis B, Theissen J, Westermann F, Brors B, and Fischer M (2010): The prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 28(21):3506-3515.
Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B (2009): Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res 15:2085-90.
Schulte JH, Horn S, Schlierf S, Schramm A, Heukamp LC, Christiansen H, Buettner R, Berwanger B, Eggert A (2009): MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett 274(1):10-15.
Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, Kenney AM, Schulte J, Beijersbergen R, Christiansen H, Berwanger B, Eilers M (2009): Stabilization of N-myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15(1):67-78.
Weber A, Marquardt J, Elzi D, Forster N, Starke S, Glaum A, Defossez PA, Yamada D, Delrow J, Eisenman RN, Christiansen H and Eilers M (2008): Zbtb4 represses transcription of p21cip1 and controls the cellular response to p53 activation. EMBO J 27:1563-1574.
Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B (2008): MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 122:699-704.
Weber A, Starke S, Bergmann E, Christiansen H (2006): The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN amplified human neuroblastomas. Clin Cancer Res 12:7316-7321.
Fulda S, Poremba C, Berwanger B, Hacker S, Eilers M, Christiansen H, Hero B, Debatin KM (2006): Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66:10016-10023.
Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, Samans B, Berwanger B, Christiansen H and Lutz W (2006): BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 34(6):1745-54.
Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, Eils R, Eggert A (2005): Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24: 7902-7912.
Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O´Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F (2005): Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23:2280-2299.
Schramm A, Schuetz V, Christiansen H, Havers W, Papoutsi M, Wilting J, Schweigerer L (2005): High activin A expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene 24:680-687.
Weber A, Imisch P, Bergmann E, Christiansen H (2004): Coamplification of DDX1 correlates with an improved survival probability in children with MYCN amplified human neuroblastoma. J Clin Oncol 22(13):2681-2690.
Weber A, Huesken C, Bergmann E, Kiess W, Christiansen NM, Christiansen H (2003): Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. Clin Cancer Res 9(15):5683-5692.
Berwanger B, Hartmann O, Bergmann E, Bernard S, Nielsen D, Krause M, Kartal A, Flynn D, Wiedemeyer R, Schwab M, Schäfer H, Christiansen H and Eilers M (2002): Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastomas. Cancer Cell 2(5):377-386.
Coy JF, Wiemann S, Bechmann I, Bächner D, Nitsch R, Kretz O, Christiansen H, Poustka A (2002): Pore membrane and/or filament interacting like protein 1 (POMFIL1) is predominantly expressed in the nervous system and encodes different protein isoforms. Gene 290:73-94.
Huang S, Lichtenauer UD, Pack S, Wang C, Kim AC, Lutchman M, Koch CA, Torres-Cruz J, Huang SC, Benz EJ,  Christiansen H, Dockhorn-Dworniczak B,  Poremba C, Vortmeyer AO, Chishti AH, Zhuang Z (2001): Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. Eur J Clin Invest 31:907-914.
Dötsch J, Repp R, Rascher W, Christiansen H (2001): Diagnostic and scientific applications of TaqMan real-time PCR in neuroblastomas. Expert Rev Mol Diagn 1(2):233-238.
Bergmann E, Wanzel M, Weber A, Shin I, Christiansen H and Eilers M (2001): Expression of p27Kip1 is prognostic and independent of MYCN amplification in human neuroblastoma. Int J Cancer 95(3):176-183.
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B (2001): Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 36(1):11-13.
Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinkschmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, Plantaz D (2001): Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there. Med Pediatr Oncol 36(1):5-10.
Poremba C, Hero B, Goertz HG, Scheel C, Wai D, Schaefer KL, Christiansen H, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B (2001): Traditional and emerging molecular markers in neuroblastoma prognosis: The good, the bad and the ugly. Klin Pädiatr 213:186-190.
Poremba C, Hero B, Heine B, Scheel C, Schaefer KL, Christiansen H, Berthold F, Kneif S, Stein H, Juergens H, Boecker W, Dockhorn-Dworniczak B (2000): Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med Pediatr Oncol 35(6):651-655.
Dötsch J, Harmjanz A, Christiansen H, Hänze J, Lampert F, Rascher W (2000): Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR. Int J Cancer 88(2):172-175.
Poremba C, Scheel C, Hero B, Christiansen H, Schäfer KL, Nakayama J, Berthold F, Jürgens H, Boecker W, Dockhorn-Dworniczak B (2000): Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma - A molecular and immunhistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 18(13):2582-2592.
Theobald M, Christiansen H, Schmidt A, Melekian B, Wolkewitz N, Christiansen NM, Brinkschmidt C, Berthold F, Lampert F (1999): Sublocalization of putative tumor suppressor gene loci on chromosome 14q in neuroblastoma. Genes Chrom Cancer 26:40-46.
Poremba C, Willenbring H, Hero B, Christiansen H, Schäfer KL, Brinkschmidt C, Jürgens H, Böcker W, Dockhorn-Dworniczak B (1999): Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol 10:1-7.
Bown N, Cotterill S, Lastowska M, O´Neill S, Pearson ADJ, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F (1999): Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1951-1961.
Dötsch J, Christiansen H, Hänze J, Lampert F, Rascher W (1998): Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept 75-76:185-190.
Erttmann R, Tafese T, Berthold F, Kerbl R, Mann J, Parker L, Schilling F, Ambros P, Christiansen H, Favrot M, Kabisch H, Hero B, Philipp T (1998): 10 years neuroblastoma screening in Europe: preliminary results of a clinial and biological review from the study group for evaluation of neuroblastoma screening in Europe (SENSE). Eur J Cancer 34:1391-1397.
Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schäfer KL, Terpe HJ, Lampert F, Boecker W, Dockhorn-Dworniczak B (1998): Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4S neuroblastomas. Br J Cancer 77:2223-2229.
George RE, Kenyon R, McGuckin AG, Kohl N, Kogner P, Christiansen H, Pearson AD, Lunec J (1997): Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 33:2037-2042. 
Berthold F, Sahin K, Hero B, Christiansen H, Gehring M, Harms D, Horz S, Lampert F, Schwab M, Terpe J (1997): The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer 33:2092-2097. 
Kiess W, Koepf G, Christiansen H, Blum WF (1997): Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor. Regul Pept 72:19-29.
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Boecker W, Lampert F, Stoerkel S (1997): Comparative genomic hybridization (CGH) analysis of neuroblastomas - an important methodical approach in pediatric tumor pathology.J Pathol 181:394-400. 
Lampert F, Christiansen H, Berner F, Terpe HJ, Berthold F (1997): Disseminated neuroblastoma under 1 year of age: Cell biology and prognosis. J Neurooncol 31:181-184.
Hänze J, Christiansen H, Schüler D, Worgall S, Lampert F, Rascher W (1996): Gene expression of neuropeptide Y and neuropeptide-Y1 receptor in relation to protooncogene tyrosine kinase A, nerve-growth-factor low-affinity-receptor and the transcription factor N-myc in human neuroblastomas. Int J Oncol 9:1183-1187.
Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Böcker W, Störkel S (1996): Synopse unbalancierter chromosomaler Aberrationen beim Neuroblastom durch Comparative Genomische Hybridisierung (CGH). Pathologe 17:368-373. 
Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, Herrmann F, Klingebiel T, Lampert F, Müller-Weihrich St, Weinel P (1996): The recurrence patterns of localised neuroblastoma: Experiences with 77 patients. Ann Oncol 7:183-187. 
Christiansen H, Sahin K, Berthold F, Hero B, Terpe HJ, Lampert F (1995): Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 31A:541-544. 
Christiansen H, Terpe HJ, Gonzales M, Wenderhold S, Berthold F, Lampert F (1995): Expression von CD44-Standard bei 182 primären Neuroblastomen. Klin Pädiatr 207:219-221.
Terpe HJ, Christiansen H, Gonzales M, Berthold F, Lampert F (1995): Differentiation and Prognosis of Neuroblastoma in correlation to the expression of CD44s. Eur J Cancer 31A:549-552. 
Christiansen H, Fuchs S, Christiansen NM, Delattre O, Theobald M, Berthold F, Lampert F (1994): Loss of the putative tumor suppressor-gene locus 1p36 as investigated by a PCR-assay and N-myc amplification in 48 neuroblastomas: Results of the German Neuroblastoma Study Group. Prog Clin Biol Res 385:19-25.
Terpe HJ, Christiansen H, Berthold F, Gonzales M, Altmannsberger M, Schulz A, Lampert F (1994): Absence of CD44 standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell Death Differ 1:123-128.
Schilling FH, Erttmann R, Ambros PF, Strehl S, Christiansen H, Kovar H, Kabisch H, Treuner J (1994): Screening for neuroblastoma. Lancet 344:1157-1158. 
Lampert F, Christiansen H, Christiansen N (1993): Numerical and structural aberrations of chromosome 1 in primary neuroblastomas: Indicators for prognostic outcome! Clin Chem Enzym Comms 5:233-236. 
Christiansen NM, Christiansen H, Berthold F, Lampert F (1993): Transcriptional activity of N-myc and NGF-r in 50 primary human neuroblastomas as predictor for clinical outcome. Int J Oncol 3:853-857. 
Christiansen H, Schestag J, Christiansen NM, Grzeschik KH, Lampert F (1992): Clinical impact of chromosome 1 aberrations in neuroblastoma: A metaphase and interphase cytogenetic study. Genes Chrom Cancer 5:141-149. 
Christiansen H, Schestag J, Bielke W, Schütz B, Rust G, Engel R, Beniers E, Christiansen NM, Lampert F (1991): Chromosome 1 interphase-cytogenetics in 32 primary neuroblastomas of different clinical stages. Prog Clin Biol Res 366:99-105.
Christiansen H, Christiansen NM, Wagner F, Altmannsberger M, Lampert F (1990): Neuroblastoma: inverse relationship between expression of N-myc and NGF-r. Oncogene 5:437-440. 
Christiansen H, Lampert F (1989): Tumorcytogenetik und Prognose beim Neuroblastom. Monatsschr Kinderheilkd 137:666-671. 
Longo L, Christiansen H, Christiansen NM, Cornaglia-Ferraris P, Lampert F (1988): N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization. J Cancer Res Clin Oncol 114:636-640. 
Lampert F, Rudolph B, Christiansen H, Franke F (1988): Identical chromosome 1p break point abnormality in the tumor and also in the constitutional karyotype (induced in vivo by radiotherapy) in a 4 year old boy with stage III neuroblastoma. Cancer Genet Cytogenet 34:235-239. 
Christiansen H, Lampert F (1988): Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 57:121-126.
Christiansen H, Franke F, Bartram CR, Adolph S, Rudolph  B, Harbott J, Reiter A, Lampert F  (1987): Evolution of tumor cytogenetic  aberrations and N-myc oncogene amplification in  a case of disseminated neuroblastoma. Cancer Genet Cytogenet 26:235-244. 
Franke F, Rudolph B, Christiansen H, Harbott J, Lampert F (1986): Tumor karyotype may be  important in the prognosis of human neuroblastoma.J Cancer Res Clin Incol 111:266-272.

Bücher / Buchkapitel

Christiansen H, Christiansen NM (2015): Progressive Neuroblastoma: Innovation and Novel Therapeutic Strategies. Karger, ISBN 978–3–318–05496–5.

Hero B, Christiansen H (2010) (2. Auflage): Neuroblastom. In: Hiddemann, Huber, Bartram (eds) Die Onkologie. Springer, pp 1656-1675.
Hero B, Christiansen H (2004): Neuroblastom. In: Hiddemann, Huber, Bartram (eds) Die Onkologie. Springer, pp 1656-1675.
Christiansen H, Christiansen NM, Berthold F, Lampert F (1992): Numerical and structural aberrations of chromosome 1, DMs and HSR, and MYCN amplification in 57 neuroblastoma tumors. In: Schwab M, Tonini GP, Benard J (eds) Human Neuroblastoma: Recent advances in clinical and genetic analysis. Harwood Academic Publishers, Switzerland, pp 176-186.
Christiansen H, Bielke W, Cremer T, Lampert F (1990): Cytogenetics of neuroblastoma in infancy. In: Lampert F, Cordero di Montezemolo L, Pession A (eds) Cancer in the first year of life. Karger, Basel, pp 129-135.

Letzte Änderung: 20.02.2016, 04:28 Uhr
Zurück zum Seitenanfang springen
Zurück zum Seitenanfang springen
Selbst. Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie